{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:52:46Z","timestamp":1697046766423},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.jhep.2004.12.012","type":"journal-article","created":{"date-parts":[[2004,12,29]],"date-time":"2004-12-29T19:16:50Z","timestamp":1104347810000},"page":"293-296","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of acute hepatitis C infection: more pieces of the puzzle?"],"prefix":"10.1016","volume":"42","author":[{"given":"Amany","family":"Zekry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2004.12.012_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome","volume":"20","author":"Alter","year":"2000","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2004.12.012_bib2","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2105\/AJPH.90.10.1562","article-title":"Estimating future hepatitis C morbidity, mortality, and costs in the United States","volume":"90","author":"Wong","year":"2000","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jhep.2004.12.012_bib3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2004.12.012_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2004.12.012_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/jhep.2003.50019","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load","volume":"37","author":"Hofer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics","volume":"39","author":"Kamal","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.20196","article-title":"Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial","volume":"39","author":"Nomura","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib8","doi-asserted-by":"crossref","first-page":"W91","DOI":"10.7326\/0003-4819-141-6-200409210-00031-w1","article-title":"Wait-and-see: an alternative approach to managing acute hepatitis C with high-dose interferon-alpha monotherapy","volume":"141","author":"Pimstone","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2004.12.012_bib9","first-page":"294","article-title":"Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients","volume":"27","author":"Rocca","year":"2003","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2004.12.012_bib10","doi-asserted-by":"crossref","first-page":"277A","DOI":"10.1016\/S0270-9139(03)80293-8","article-title":"24 weeks of monotherapy with pegylated interferon alfa-2b in patients with acute hepatitis C infection","volume":"38","author":"Wiegand","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24-week course of PEG-interferon \u03b1-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2004.12.012_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jhep.2004.11.018","article-title":"Barriers to interferon \u03b1 therapy are higher in intravenous drug users than in other patients with acute hepatitis C","volume":"42","author":"Broers","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2004.12.012_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2036.2004.02023.x","article-title":"Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response","volume":"20","author":"Delwaide","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2004.12.012_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.20291","article-title":"Long-term follow-up after successful interferon therapy of acute hepatitis C","volume":"40","author":"Wiegand","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib15","first-page":"1","volume":"19","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"10.1016\/j.jhep.2004.12.012_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/00365540310013252","article-title":"Chronic hepatitis C: updated Swedish consensus","volume":"35","author":"Wejstal","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jhep.2004.12.012_bib17","first-page":"467","article-title":"Treatment of hepatitis C Paris 27\u201328 February 2002","volume":"153","year":"2002","journal-title":"Ann Med Interne (Paris)"},{"issue":"17","key":"10.1016\/j.jhep.2004.12.012_bib18","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.1990.03450170079026","article-title":"Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection","volume":"264","author":"Alter","year":"1990","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jhep.2004.12.012_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jurban\/jth153","article-title":"Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care","volume":"81","author":"Sylvestre","year":"2004","journal-title":"J Urban Health"},{"key":"10.1016\/j.jhep.2004.12.012_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-129-7-199810010-00012","article-title":"Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease","volume":"129","author":"Lerner","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2004.12.012_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM200107193450312","article-title":"Treatment of chronic hepatitis C in active drug users","volume":"345","author":"Davis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2004.12.012_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0399-8320(04)95008-7","article-title":"Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit","volume":"28","author":"Cournot","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2004.12.012_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/gut.50.5.693","article-title":"Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population","volume":"50","author":"Kondili","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2004.12.012_bib26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep.20221","article-title":"Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C","volume":"39","author":"Wedemeyer","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0168-8278(03)00461-6","article-title":"When and how to treat acute hepatitis C?","volume":"39","author":"Licata","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2004.12.012_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2004.02.041","article-title":"Acute hepatitis C virus infection: to treat or not to treat?","volume":"126","author":"Jaeckel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2004.12.012_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/hep.510380302","article-title":"The German Network of excellence for viral hepatitis (Hep-Net)","volume":"38","author":"Manns","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2004.12.012_bib30","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1053\/j.gastro.2004.02.049","article-title":"Acute hepatitis C virus infection: to treat or not to treat?","volume":"126","author":"Gerlach","year":"2004","journal-title":"Gastroenterolgy"},{"key":"10.1016\/j.jhep.2004.12.012_bib31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0168-8278(04)90469-2","article-title":"Short course of Pegylated interferon alfa-2b in acute HCV hepatitis","volume":"40","author":"Calleri","year":"2004","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827804006178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827804006178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T09:23:18Z","timestamp":1548840198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827804006178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0168827804006178"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2004.12.012","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}